Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

医学 贝伐单抗 氟尿嘧啶 结直肠癌 内科学 外科 胃肠病学 置信区间 化疗 临床研究阶段 癌症
作者
Fairooz F. Kabbinavar,Herbert I. Hurwitz,Louis Fehrenbacher,Neal J. Meropol,William Novotny,Grazyna Liebérman,S. Griffing,Emily K. Bergsland
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:21 (1): 60-65 被引量:1707
标识
DOI:10.1200/jco.2003.10.066
摘要

This phase II trial investigated the safety and efficacy of two doses of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, plus fluorouracil (FU)/leucovorin (LV) versus FU/LV alone in patients with metastatic colorectal cancer.One hundred four previously untreated patients with measurable metastatic colorectal cancer were randomly assigned to one of the following three treatment groups: 36 to FU (500 mg/m(2))/LV (500 mg/m(2)) alone, 35 to FU/LV + low-dose bevacizumab (5 mg/kg every 2 weeks), and 33 to FU/LV + high-dose bevacizumab (10 mg/kg every 2 weeks). FU/LV was given weekly for the first 6 weeks of each 8-week cycle.Compared with the FU/LV control arm, treatment with bevacizumab (at both dose levels) plus FU/LV resulted in higher response rates (control arm, 17%, 95% confidence interval [CI], 7% to 34%; low-dose arm, 40%, 95% CI, 24% to 58%; high-dose arm, 24%, 95% CI, 12% to 43%), longer median time to disease progression (control arm, 5.2 months, 95% CI, 3.5 to 5.6 months; low-dose arm, 9.0 months, 95% CI, 5.8 to 10.9 months; high-dose arm, 7.2 months, 95% CI, 3.8 to 9.2 months), and longer median survival (control arm, 13.8 months; 95% CI, 9.1 to 23.0 months; low-dose arm, 21.5 months, 95% CI, 17.3 to undetermined; high-dose arm, 16.1 months; 95% CI, 11.0 to 20.7 months). After cross-over, two of 22 patients had a partial response to bevacizumab alone. Thrombosis was the most significant adverse event and was fatal in one patient. Hypertension, proteinuria, and epistaxis were other potential safety concerns.The encouraging results of this randomized trial support further study of bevacizumab 5 mg/kg plus chemotherapy as first-line therapy for metastatic colorectal cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
Poik完成签到,获得积分10
2秒前
刘娅铷发布了新的文献求助10
2秒前
4秒前
小小吴完成签到,获得积分10
5秒前
不孤独的发卡完成签到,获得积分20
5秒前
潘善若发布了新的文献求助30
8秒前
zzzjh完成签到,获得积分10
8秒前
香蕉觅云应助超级采纳,获得10
10秒前
10秒前
安然完成签到 ,获得积分10
15秒前
桔子完成签到,获得积分10
15秒前
15秒前
落后的哈密瓜完成签到,获得积分10
16秒前
潘善若发布了新的文献求助10
17秒前
Rainbow完成签到 ,获得积分10
18秒前
20秒前
SciGPT应助momo采纳,获得10
20秒前
20秒前
Lili完成签到,获得积分10
21秒前
21秒前
22秒前
congyjs完成签到,获得积分20
24秒前
超级发布了新的文献求助10
25秒前
25秒前
潘善若发布了新的文献求助10
26秒前
Rondab应助胡图图采纳,获得10
26秒前
26秒前
28秒前
nilu完成签到,获得积分10
28秒前
congyjs发布了新的文献求助10
29秒前
30秒前
CodeCraft应助落后的哈密瓜采纳,获得10
30秒前
30秒前
王汉韬发布了新的文献求助10
31秒前
Nature_Science完成签到,获得积分10
31秒前
32秒前
lihan完成签到,获得积分10
33秒前
33秒前
34秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158